---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-010075"
form_type: "8-K"
ticker: "NKTX"
cik: "0001787400"
company_name: "Nkarta, Inc."
filed_at: "2022-05-16T23:59:59+00:00"
generated_at: "2026-06-25T15:17:28.078232+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Nkarta CMO Kanya Rajangam resigns; David Shook named VP Clinical Development

## Summary
- Dr. Kanya Rajangam resigns as CMO effective June 5, 2022, to oversee R&D at a private biotech.
- Dr. David Shook appointed VP Clinical Development, leading all clinical and regulatory activities.
- Shook is a practicing pediatric hematologist/oncologist and early NK cell therapy pioneer.
- Nkarta's NKX101 and NKX019 programs continue; expects to submit updated data for a medical meeting in 2022.

## SEC filing metadata
- accession: 0000950170-22-010075
- form_type: 8-K
- ticker: NKTX
- cik: 0001787400
- company_name: Nkarta, Inc.
- filed_at: 2022-05-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787400/000095017022010075/0000950170-22-010075-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787400/000095017022010075/nktx-20220513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-010075
- JSON: https://secwatch.observer/filing/0000950170-22-010075.json
- Plain text: https://secwatch.observer/filing/0000950170-22-010075.txt

## Key facts
- Executive change
  Dr. David Shook was appointed as Vice President, Clinical Development at Nkarta, Inc..
  - Action: appointed
  - Role: Vice President, Clinical Development
  source text: On May 16, 2022, the Company issued a press release announcing the resignation of Dr. Rajangam and the appointment of Dr. David Shook as Vice President, Clinical Development.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787400/000095017022010075/0000950170-22-010075-index.htm
- Executive change
  Dr. Kanya Rajangam resigned as Chief Medical Officer at Nkarta, Inc..
  - Action: resigned
  - Role: Chief Medical Officer
  source text: On May 13, 2022, Dr. Kanya Rajangam notified Nkarta, Inc. (the “Company”) of her decision to resign as Chief Medical Officer of the Company to oversee research and development activities at a private biotechnology company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787400/000095017022010075/0000950170-22-010075-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.